Betamethasone/calcipotriol - Novartis

Drug Profile

Betamethasone/calcipotriol - Novartis

Alternative Names: BFH 772; Calcipotriol/betamethasone - Novartis

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Corticosteroids; Cyclohexanes; Dihydroxycholecalciferols; Fluorinated steroids; Indenes; Pregnadienetriols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Psoriasis; Rosacea

Most Recent Events

  • 29 Feb 2012 Novartis completes a phase II trial in Rosacea in USA (NCT01449591)
  • 30 Sep 2011 Phase-II clinical trials in Rosacea in USA (Topical)
  • 27 Apr 2010 Novartis completes a phase I/II trial in Psoriasis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top